Survodutide
Neutral, BioHarmony verdict
BioHarmony score 5.1 out of 10
Survodutide (BI 456906) is an investigational once-weekly GLP-1 and glucagon dual agonist that drove up to 16.6% weight loss in Phase 3, per the Boehringer Ingelheim SYNCHRONIZE-1 topline, and 62% liver-disease improvement on its best Phase 2 dose, per Sanyal 2024.
Read full reportWhat is Survodutide?
Survodutide, also called BI 456906, is an investigational injectable peptide that hits two receptors at once: GLP-1 and glucagon. The GLP-1 arm is the familiar one. It blunts appetite and slows the stomach, the same way semaglutide does. The glucagon arm is the twist. It tells the liver to burn its own fat and adds a little extra heat production on top.
From the BioHarmony report, reviewed Sep 8, 2026.
Saved on this device only.
How it is thought to work
GLP-1 arm cuts appetite and slows the gut; glucagon arm burns liver fat and adds thermogenesis
Safety watch-outs
- Severe, persistent stomach pain that may travel to the back (possible pancreatitis): stop and seek care.
- Relentless vomiting with signs of dehydration: stop and consult a clinician.
- New or worsening fast or irregular heartbeat: reduce dose or stop and get evaluated.
- Any personal or family history of medullary thyroid cancer or MEN 2: do not use, consistent with the GLP-1 class warning.
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
No approved-label or study protocol is recorded for Survodutide yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
Survodutide is an investigational glucagon and GLP-1 dual receptor agonist developed by Boehringer Ingelheim under a partnership with Zealand Pharma. Registered phase 3 studies cover obesity and metabolic dysfunction-associated steatohepatitis, and there is no FDA-approved survodutide product.
Primary sources
- LIVERAGE: phase 3 study of survodutide in metabolic dysfunction-associated steatohepatitis and liver fibrosis ClinicalTrials.gov, U.S. National Library of Medicine,
- Phase 3 study of the effect of survodutide on cardiovascular safety in people living with obesity ClinicalTrials.gov, U.S. National Library of Medicine,
- Zealand Pharma Announces Financial Results for the First Nine Months of 2024 (Company Announcement No. 49/2024, Q3 2024 Interim Report) Zealand Pharma A/S,
Related peptides for weight & metabolic
- 6.1TirzepatideTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
- 6.0MOTS-cMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
- 6.0TesamorelinTesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for…
- 5.9Semaglutide (GLP-1 Agonist)Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.